enter passkey to continue
incorrect passkey
The promise of precision medicine depends on one condition: that it works for everyone. Today, it doesn't. Americana Genetics is building the case for inclusive genomic infrastructure that serves every population in America.
Genomic databases were built on a narrow foundation. The clinical consequences are measurable, inequitable, and preventable.
Source: GWAS Catalog ancestry representation data
Nearly 80% of participants in genome-wide association studies are of European descent. Yet the resulting reference panels, variant classifications, and risk scores are applied universally across clinics serving the most diverse population on Earth.
The result is not just a scientific gap. It is a clinical one. Variants that would be classified as benign in a European-ancestry patient are classified as "variants of uncertain significance" in patients of African, Hispanic, Indigenous, and Asian ancestry -- not because they are more complex, but because the data to interpret them does not yet exist.
A VUS is not a neutral finding. It is a diagnostic dead end that extends the odyssey, delays treatment, and costs the system money.
The representation gap is not abstract. It produces concrete, measurable harm in clinical settings across the country every day.
Variants in genes like MYBPC3 and TTN have been misclassified as pathogenic in patients of African ancestry because population-specific allele frequencies were absent from reference databases. The result: false diagnoses of hypertrophic cardiomyopathy, unnecessary cascade screening of families, and clinical decisions built on incomplete data.
Reclassification rate: up to 10% of reported variantsHispanic and Latino populations carry founder variants and admixture-specific alleles that are poorly represented in current clinical databases. Diagnostic yield for rare disease genetic testing is measurably lower in these populations -- not because the diseases are absent, but because the interpretive infrastructure was not built to find them.
Diagnostic yield gap: 10-15% lowerPharmacogenomic guidelines for drugs like warfarin, clopidogrel, and codeine were calibrated using European-ancestry cohorts. CYP2D6, CYP2C19, and other metabolizer alleles vary dramatically across populations. Patients of African and East Asian ancestry face higher rates of adverse drug events and therapeutic failure when standard dosing algorithms are applied without ancestry-informed adjustment.
2-3x variation in metabolizer phenotype frequencyPolygenic risk scores developed in European populations lose up to 80% of their predictive accuracy when applied to individuals of African ancestry. These scores are increasingly used to guide clinical decisions around cancer screening, cardiovascular risk, and preventive care -- meaning the patients who need precision medicine most are the ones it serves least.
Up to 80% accuracy loss across populationsEquitable genomic medicine requires deliberate investment across four interconnected domains. None alone is sufficient. Together, they constitute the infrastructure of inclusive precision medicine.
Large-scale biobanking initiatives must prioritize recruitment from underrepresented populations -- not as an afterthought, but as a foundational design principle. Programs like All of Us, H3Africa, and the Million Veteran Program are expanding the reference base, but clinical-grade diversity in variant databases remains years behind. Payer and health system investment in diverse biobanks is an investment in diagnostic accuracy for their own member populations.
Variant interpretation depends on knowing how common a variant is in a given population. Without ancestry-matched reference panels, laboratories cannot distinguish rare pathogenic variants from common benign ones. Building and curating these panels for African American, Hispanic, Indigenous, South Asian, and Pacific Islander populations is the single highest-leverage intervention for reducing VUS rates and improving diagnostic yield across the board.
Access to genetic testing correlates with geography, insurance status, and race. Rural communities, Medicaid-covered populations, and communities of color face structural barriers to genetic services -- fewer genetic counselors, longer wait times, lower referral rates, and more restrictive coverage policies. CarePathway models must be designed with access equity as a core metric, not an optional add-on.
Genetic counseling is the critical human interface in genomic medicine. It is also one of the least diverse professions in healthcare: over 90% of genetic counselors in the U.S. are white. Building a counseling workforce that reflects the populations it serves -- and training all counselors in culturally responsive communication -- is essential for informed consent, patient trust, and clinical follow-through.
Genomic medicine will either deepen health disparities or close them. There is no neutral path. Every reference panel that excludes a population, every risk score calibrated on a single ancestry, every coverage policy that restricts access to testing -- these are choices that compound over time into systemic inequity.
The United States is the most genetically diverse nation in history. That diversity is not a challenge to overcome. It is the reason genomic medicine matters here more than anywhere else -- and the reason it must be built to serve everyone.
"The infrastructure we build today determines who benefits from precision medicine tomorrow. Americana Genetics exists to ensure the answer is: all of us."